NEW YORK: Ruder Finn’s healthcare practice has added dollars 6 million in new accounts over the last few months, revitalizing the agency’s business in the arthritis, cardiology and dermatology sectors.
NEW YORK: Ruder Finn’s healthcare practice has added dollars 6
million in new accounts over the last few months, revitalizing the
agency’s business in the arthritis, cardiology and dermatology
Among the wins were two Novartis pharmaceuticals, Impact (a liquid
nutritional supplement) and Zelmac (a treatment for irritable bowel
syndrome). Other companies who have entrusted at least a piece of their
business to the agency include Pfizer, Pharmanex, Searle and Solvay
The wins represent validation for RF executive vice president and
director of healthcare Paul McDade, who joined the agency a little over
a year ago and was charged with revitalizing the practice.
He oversaw a restructuring within the healthcare operation, and has
stressed an organic growth philosophy that seems to be paying off.
Witness the new business from Pfizer - RF had quietly been one of the
key parties behind the Viagra launch.
’These clients put us at a 30% growth rate for the first half of 1999,’
he said. ’It’s a testament to the talent and commitment of our
healthcare professionals worldwide.’
Healthcare is RF’s largest practice area. The firm’s 1998 billings
within the sector of dollars 18.1 million placed it sixth on PRWeek’s
annual ranking of healthcare PR practices.
McDade previously worked for Edelman healthcare.